Upgrade to SI Premium - Free Trial

Merck (MRK) Defended at BMO Capital

October 30, 2017 1:13 PM
BMO Capital analyst Alex Arfaei came out to defend Merck (NYSE: MRK) which is down 5.9% after the company announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change

Next Articles